Syquant Capital SAS’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Syquant Capital SAS’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-153,920	Closed	-$9.04M	–	13
2023 Q4	$9.04M	Buy	+153,920	New	+$8.65M	40.81%	1

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Syquant Capital SAS's MRTX Position: Q1 2024 in Review

Syquant Capital SAS sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 153,920 shares — an estimated $9.04M sold.

Syquant Capital SAS first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $9.04M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Syquant Capital SAS reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Syquant Capital SAS sold 153,920 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $9.04M.
Syquant Capital SAS first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Syquant Capital SAS's Mirati Therapeutics, Inc. Common Stock position peaked at $9.04M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Syquant Capital SAS's 13F filing for Q1 2024, filed 9 Apr 2024.